Claudin 18.2 Targeted Therapy Market Trends Are Creating New Opportunities For Industry Leaders
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Claudin 18.2 Targeted Therapy Market Growth From $1.98 Billion In 2026 To $4.6 Billion By 2030 At A CAGR Of 23.5%
The market for claudin 18.2 targeted therapies has experienced remarkable expansion in recent years. Projections indicate a rise from $1.6 billion in 2025 to $1.98 billion in 2026, reflecting a compound annual growth rate (CAGR) of 23.7%. This historical growth has been driven by factors such as the growing incidence of gastric and gastrointestinal cancers, progress in antibody engineering techniques, an increase in oncology-focused clinical trials, enhanced funding for targeted cancer treatments, and a deeper comprehension of claudin protein biology.
The market for claudin 18.2 targeted therapies is anticipated to experience explosive expansion over the coming years. By 2030, its value is projected to reach $4.61 billion, reflecting a compound annual growth rate (CAGR) of 23.5%. This forecasted growth is driven by various factors, including a rise in regulatory approvals for oncology drugs aimed at specific targets, an increasing demand for customized cancer treatments, the broadening of combination therapy strategies, heightened investment in oncology pipelines, and a growing reliance on precision diagnostic tools. Key developments shaping this period involve an intensified emphasis on biomarker-driven cancer therapies, progress in creating claudin 18.2 monoclonal antibodies, a widening scope of targeted treatments for particular indications, improved incorporation of companion diagnostics, and a surge in collaborative initiatives within the precision oncology sector.
Download A Free Sample Report For Comprehensive Market Insights:
Claudin 18.2 Targeted Therapy Market Development Factors: Which Trends Are Supporting Demand?
The increasing prevalence of gastrointestinal cancers is anticipated to drive expansion in the claudin 18.2 targeted therapy market moving forward. Gastrointestinal (GI) cancers are malignant tumors found anywhere along the digestive tract, extending from the esophagus to the rectum. This rise in GI cancers is primarily driven by poor dietary habits, including consumption of processed foods and insufficient fiber intake, which promotes gut inflammation and heightens cancer risk. Claudin 18.2 targeted therapy addresses GI cancers by specifically targeting the Claudin 18.2 protein, which is overexpressed on cancerous cells, allowing drugs or antibodies to destroy cancer cells while preserving healthy tissue and boosting treatment efficacy. For example, in June 2025, the Centers for Disease Control and Prevention (CDC), a US public health agency, reported 147,931 new colorectal cancer cases in 2022 and 53,779 colorectal cancer deaths in 2023. Consequently, the rising incidence of GI cancers is fueling growth in the claudin 18.2 targeted therapy market.
Claudin 18.2 Targeted Therapy Market Segment Analysis And Revenue Opportunities
The claudin 18.2 targeted therapy market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies
3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors
Claudin 18.2 Targeted Therapy Market Transformation Trends: Which Innovations Are Driving Change?
Major players in the claudin 18.2 targeted therapy space are actively advancing new approaches, including monoclonal antibodies, engineered to precisely recognize and attack cancer cells that express claudin 18.2, ultimately improving therapeutic results. A monoclonal antibody is a lab-created protein engineered to attach specifically to one target, such as a protein on the surface of malignant cells, thereby enabling the immune system to better identify and eliminate those cells. One example is from March 2024, when Astellas Pharma Inc., a pharmaceutical firm headquartered in Japan, secured approval from Japan’s Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab), intended for patients with CLDN18.2-positive cancer. This targeted therapy is designed for advanced gastric and gastroesophageal junction cancer, selectively connecting to the CLDN18.2 protein present on tumor cells, which triggers an immune response to destroy these cancerous cells. Findings from clinical trials indicate that, when paired with chemotherapy, this treatment markedly extends both progression-free and overall survival compared to chemotherapy alone. By offering an innovative and effective option for individuals with HER2-negative, CLDN18.2-positive tumors, this new therapy addresses a critical unmet need in the aggressive forms of gastric cancer.
Claudin 18.2 Targeted Therapy Market Leading Players Shaping Industry Direction
Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.
Access The Complete Claudin 18.2 Targeted Therapy Market Report:
Claudin 18.2 Targeted Therapy Market Regional Distribution: Which Areas Drive Market Expansion?
Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2025. The regions covered in the claudin 18.2 targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
